Compare Fubotv Inc (FUBO) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Fubotv Inc trades at $9.6 (market cap $1.00B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 83.2× Fubotv Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Fubotv Inc pays none. Which is the better fit depends on your goals.
| FUBO | REGN | |
|---|---|---|
Market Cap | $1.00B | $83.19B |
Sector | Technology | Health |
52-Week High | $54.72 | $812.27 |
52-Week Low | $8.09 | $555.51 |
Enterprise Value | $1.18B | $77.90B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.26, up 3.0% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue growth to $1.62B in 2024 and projected net income of $123M for 2025. Valuation metrics appear attractive with P/E of 2.41 and P/S of 0.18, while analyst consensus targets $15.33 with 47% buy ratings.
FUBO presents a turnaround story with improving profitability and deep valuation discounts, though negative cash flows and high debt levels pose execution risks. The appointment of former Disney executive Alisa Bowen as CEO and strategic partnerships provide catalysts, but competitive pressures in streaming require careful monitoring for sustained growth.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
